莫基奥症候群治疗药物的市场规模、份额和成长分析（按治疗方法、疾病类型、分销管道和地区）：产业预测（2025-2032）

2023年全球莫基奥症候群治疗药物市场规模为1.556亿美元，从2024年的1.6462亿美元成长到2032年的2.5845亿美元，在预测期内（2025年-2032年）预计复合年增长率为5.8% 。

Morquio 症候群被归类为黏多醣症(MPS IV)，是一种罕见的遗传代谢性疾病，主要影响骨骼，其特征是无法代谢Glico。由于患病率上升、政府和企业支持的增加以及对解决併发症的专用药物的需求不断增加，全球莫基奥症候群治疗药物市场正在显着增长。医疗保健成本上升和技术进步推动了製造商之间的策略合併和联盟，旨在增加治疗选择。临床试验也在扩大，从 2022 年到 2028 年提供了利润丰厚的机会。然而，报销政策不足和製造成本高昂等挑战可能会阻碍市场扩张，再加上大众对治疗方案的认识较低，这可能会阻碍市场的扩张。

目录

介绍

• 分析目的
• 市场范围
• 定义

分析方法

• 资讯采购
• 次要/主要资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 市场概况及展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特分析

主要市场考虑因素

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场魅力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究

莫基奥症候群治疗药物的全球市场规模和复合年增长率：按治疗方法分类（2025-2032）

• 市场概况
• 酵素替代疗法
• 其他的

莫基奥症候群治疗药物的全球市场规模和复合年增长率：按疾病类型划分（2025-2032）

• 市场概况
• 莫尔基奥A
• 莫尔基奥B

莫基奥症候群治疗药物的全球市场规模和复合年增长率：按分销管道划分（2025-2032）

• 市场概况
• 医院药房
• 零售药房
• 网路药房
• 其他的

Morquio症候群治疗药物全球市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要企业采取的策略
• 近期市场趋势
• 主要企业市场占有率（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• BioMarin 製药公司（美国）
• 健赞公司（美国）
• Shire plc (Ireland)
• JCR製药有限公司（日本）
• 赛诺菲（法国）
• Sangamo Therapeutics（美国）
• ArmaGen, Inc.（美国）
• 绿十字株式会社（韩国）
• Concert Pharmaceuticals Inc.（美国）
• 亚力兄製药公司（美国）
• 诺和诺德公司（丹麦）
• 礼来公司（美国）
• 勃林格殷格翰国际有限公司（德国）
• AstraZeneca (UK)
• 安进公司（美国）
• 默克公司（德国）
• Actelion 製药股份有限公司（瑞士）
• 比康（印度）
• Ultragenyx 製药公司（美国）
• Enzyvant Therapeutics Inc.（美国）

结论和建议

Global Morquio Syndrome Treatment Market size was valued at USD 155.6 million in 2023 and is poised to grow from USD 164.62 million in 2024 to USD 258.45 million by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

Morquio syndrome, categorized under mucopolysaccharidosis (MPS IV), is a rare inherited metabolic disorder primarily affecting the skeleton, characterized by the body's inability to metabolize glycosaminoglycans. The global treatment market for Morquio syndrome is witnessing significant growth driven by the rising prevalence of the condition, increased governmental and corporate support, and heightened demand for specialized medications addressing its complications. Strategic mergers and partnerships among manufacturers aim to enhance treatment options, supported by rising healthcare expenditure and technological advancements. Clinical trials are also expanding, presenting lucrative opportunities from 2022 to 2028. However, challenges such as inadequate reimbursement policies and high production costs may impede market expansion, compounded by low public awareness regarding treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Morquio Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Morquio Syndrome Treatment Market Segmental Analysis

Global Morquio Syndrome Treatment Market is segmented by Treatment, Disease Type, Distribution Channel and region. Based on Treatment, the market is segmented into Enzyme Replacement Therapy and Others. Based on Disease Type, the market is segmented into Morquio A and Morquio B. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Morquio Syndrome Treatment Market

The Morquio Syndrome Treatment market is anticipated to experience significant growth, driven primarily by an upsurge in the number of therapeutic products entering both early and advanced research stages. There is an increasing emphasis on addressing rare diseases, which further fuels market expansion. Numerous pharmaceutical companies are actively developing new medications that, depending on their clinical trial outcomes, are expected to receive regulatory approvals. The recent authorization of elosulfase alfa (VIMIZIM) underscores the potential for additional treatments to reach the market, which is expected to stimulate interest and investment in Morquio Syndrome therapies.

Restraints in the Global Morquio Syndrome Treatment Market

One significant challenge facing the global Morquio Syndrome treatment market is the prohibitive cost associated with treatment options, notably VIMIZIM, which can reach approximately US$ 380,000 per year for patients. This financial burden limits accessibility for many who require these therapies. Furthermore, the market is hindered by a lack of awareness surrounding Morquio Syndrome in developing regions, which contributes to delayed diagnoses and treatments. Additionally, various clinical and regulatory challenges present further obstacles to market growth, complicating the landscape for both patients and healthcare providers seeking effective therapeutic solutions for this rare condition.

Market Trends of the Global Morquio Syndrome Treatment Market

The Global Morquio Syndrome Treatment market is experiencing a notable upward trend, driven by heightened research and development activities from key players and recent regulatory advancements. Pharmaceutical companies, including Ultragenyx Pharmaceutical Inc. and Shire, are actively conducting Phase 3 studies and clinical trials targeting various demographics affected by the syndrome. Moreover, innovative treatments, such as AGT 181 from ArmaGen, are emerging through clinical testing, reflecting a growing commitment to addressing this rare genetic disorder. Increased public awareness and understanding of Morquio syndrome further propel market growth, signaling a promising future for effective treatment options and improving patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Morquio Syndrome Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Enzyme Replacement Therapy
• Others

Global Morquio Syndrome Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Morquio A
• Morquio B

Global Morquio Syndrome Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Morquio Syndrome Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Disease Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Disease Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Disease Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Disease Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Disease Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• BioMarin Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genzyme Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ArmaGen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GREEN CROSS CORP (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Concert Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actelion Pharmaceuticals Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultragenyx Pharmaceutical Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzyvant Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations